Eli Lilly (LLY) in Pivotal Point Check: Pharmaceutical Giant Breaks Trillion-Dollar Mark - 43% Revenue Increase and Mega Outlook for 2026 Makes Rival Novo Nordisk Look Old!
Reading Time: 3 minutes
For the 4th quarter of 2025, a revenue jump of 43% to $19.3 billion was reported. Sales of Mounjaro and Zepbound have nearly doubled and are significantly boosting profitability. 2026 aims for revenue of up to $83 billion, significantly above analysts' estimates. The world-leading pharmaceutical company focusing on the treatment of diabetes, obesity, and oncology thrilled investors on Wednesday, February 4. The stock surged around 10% and once again surpassed the historical market capitalization of $1 trillion. The trigger...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
